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A PHARMACOECONOMIC OUTCOMES ANALYSIS
COMPARING RISPERIDONE LONG-ACTING INJECTION AND
CONVENTIONAL DEPOT ANTIPSYCHOTICS
Snaterse M,Welch R
Capital Health, Edmonton, AB, Canada
OBJECTIVES: To assess the effectiveness and economic impact
of treatment with risperidone long-acting injection (RLAI) in
patients with schizophrenia and matched patients prescribed
conventional depot antipsychotics (CDA) using a naturalistic,
retrospective chart review design. METHODS: Records were
obtained for forty inpatients initiated on RLAI and 49 inpa-
tients initiated on a CDA from March–June 2004 at the
Alberta Hospital Edmonton. Discharge and readmission rates
were evaluated after 1 year of treatment and a further phar-
macoeconomic evaluation comparing global costs of treatment
was completed 2 years post initiation. RESULTS: There were
no statistically signiﬁcant differences between the cohorts with
respect to age, gender, number of previous psychiatric admis-
sions and admission GAF scores. Post-discharge follow-up care
was similar for both cohorts. After 1 year of treatment, dis-
charge rates for RLAI and CDA were 83% and 58% and read-
mission rates were 0% and 26% respectively. After 2 years of
treatment, discharge rates for RLAI and CDA were 87% and
66% and readmission rates 19% vs. 29% respectively. Mean
days of hospitalization per patient over the second year of
treatment was 73 days for RLAI and 171 days for CDA. Mean
cost of treatment, including inpatient hospitalization and medi-
cation costs, was $57,414 per patient for RLAI and $123,975
per patient for CDA, representing a cost savings of $66,561 per
patient per annum. All comparisons reached statistical signiﬁ-
cance (p < 0.05). Secondary measures of effectiveness and tol-
erability revealed that treatment with RLAI was associated with
a reduction in antipsychotic polypharmacy as well as a reduced
need for anticholinergic rescue medications. CONCLUSION: In
this difﬁcult to treat patient population, RLAI conferred signiﬁ-
cant advantages over CDA in terms of effectiveness and toler-
ability. Differences in discharge and readmission rates, as well
as an overall reduction in hospitalization, resulted in signiﬁcant
pharmacoeconomic advantages.
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SERTINDOLE INTHETREATMENT OF SCHIZOPHRENIA IN
POLAND:A COST ANALYSIS
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OBJECTIVES: To evaluate the clinical outcomes and costs of
sertindole versus risperidone in the treatment of schizophrenia
in Poland, when considering the ECG measurements required
for prescribing sertindole. METHODS: A 6-month cost analysis
of a randomized, double-blind, parallel-group, ﬂexible-dose,
multi-centre study was performed, for which the efﬁcacy and
tolerability of sertindole were directly compared with risperi-
done. The health outcomes observed in this clinical trial were
percentage of patients experiencing response (deﬁned as a 50%
reduction on the PANSS); experiencing EPS-related adverse
events (AEs); and experiencing insomnia/agitation as an adverse
event. For the cost analysis these were converted into 6-month
rates and associated with a treatment cost. To estimate the total
cost of treatment of schizophrenia in Poland a survey among 5
Polish clinical experts was conducted assessing the resource uti-
lization for responding and non-responding patients, and for
treatment of the adverse events. The cost of treatment included
the cost of the antipsychotic agent, the treatment of the adverse
events, and the cost of response or non-response. RESULTS:
The 12-week health outcomes observed in the clinical trial
were: response rates of 42.2% and 32.9% for sertindole and
risperidone, respectively; 19% and 28% of patients experienc-
ing EPS-related AEs for sertindole and risperidone, respectively;
and 9.3% and 12.4% of patients experiencing insomnia/
agitation as an adverse event for sertindole and risperidone,
respectively. The total estimated 6-month costs of treating a
patient in Poland responding to antipsychotic treatment is
10.046 PLN, and for a non-responding patient 25.929 PLN.
When the health outcomes are extrapolated to 6 months, and
the 6-month costs are applied, the total cost of 6-month treat-
ment with sertindole is 18.305 PLN as compared with 19.448
PLN with risperidone. CONCLUSION: Sertindole is therefore
a less costly antipsychotic-treatment option in Poland, despite
the additional costs of ECGs (30 PLN).
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A COST-UTILTY ANALYSIS OF ATOMOXETINE AGAINST
CURRENT STIMULANTTHERAPIES FORTHETREATMENT OF
CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY
DISORDER (ADHD) IN GERMANY
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OBJECTIVES: To estimate the cost-effectiveness of atomoxet-
ine, a non-stimulant alternative for the treatment of children
with ADHD, compared to currently used stimulant therapies
in Germany. METHODS: The economic analysis employs a
Markov process to estimate the incremental cost per QALY
gained by the introduction of atomoxetine compared to pre-
vailing treatment options in Germany including extended
release methylphenidate (XR-MPH) and immediate release
methylphenidate (IR-MPH). The economic model is calculated
for three discrete patient populations; stimulant-naïve patients,
stimulant-failure patients and patients with unmanageable
contra-indicated comorbid conditions. Utility values were
derived from a survey of 83 parents of children with ADHD.
The effectiveness and safety aspects of the various treatment
options, based on a thorough review of controlled clinical trials
and other clinical literature, were validated by clinical experts.
Cost values were estimated from the perspective of the German
health service. Expected cost and outcome values were calcu-
lated over one year. RESULTS: In the stimulant-naïve popula-
tion, the ICER of atomoxetine was estimated at €18,227 per
QALY gained compared with IR-MPH, and €7,778 per QALY
gained compared with XR-MPH. In the stimulant-failure popu-
lation, the ICER of atomoxetine was estimated at €14,385 per
QALY gained compared with no medication. In the stimulant
contra-indicated population, the ICER of atomoxetine was
estimated at €14,916 per QALY gained compared with no
medication. Sensitivity analyses showed that the results of the
model were robust to changes in most important variables
with the utility values being important indicators of the cost-
effectiveness of atomoxetine. CONCLUSION: The incremental
cost per QALY gained of atomoxetine compared to current
treatment options suggests that atomoxetine offers a value-for-
money alternative in the treatment of children with ADHD in
Germany.
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